Investigation into Boston Scientific Securities Litigation Announced
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy BSX?
Source: Globenewswire
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, particularly for investors who purchased securities between July 23, 2025, and February 3, 2026, urging them to seek lead plaintiff status by the May 4, 2026 deadline.
- Disappointing Performance: Boston Scientific's February 4, 2026 earnings report revealed that its U.S. electrophysiology (EP) sales fell short of expectations, resulting in a significant net income miss and a 17.6% stock price drop to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives violated federal securities laws by failing to disclose the unsustainable growth rate of the EP segment, severely undermining investor confidence and impacting market expectations for future performance.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with relevant information, including former employees and shareholders, to contact the firm to support the ongoing class action lawsuit, ensuring that investors' legal rights are upheld.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.000
Low
94.00
Averages
108.14
High
132.00
Current: 62.000
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Boston Scientific Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Performance Miss Impact: Boston Scientific's February 4, 2026, earnings report revealed disappointing U.S. EP sales, resulting in a significant net income miss and a 17.6% drop in stock price to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives failed to disclose the true state of the U.S. EP segment's growth, leading to a severe loss of investor confidence and negatively impacting market expectations for future performance.
- Legal Rights Reminder: Faruq & Faruq LLP encourages anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to come forward to assist in the litigation process.
See More
Boston Scientific Class Action Lawsuit Notice
- Class Action Timeline: Purchasers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, have until May 4, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential legal risks.
- Allegations Overview: The lawsuit alleges that Boston Scientific and its executives made false or misleading statements during the class period, failing to disclose risks from increased market competition and unmet revenue expectations, which could undermine investor confidence.
- Financial Performance Disclosure: On February 4, 2026, Boston Scientific reported fourth-quarter and full-year 2025 results, revealing a net income increase to $672 million, yet the earnings per share (EPS) fell short of guidance, leading to a stock price drop of over 17%, reflecting market apprehension about the company's outlook.
- Legal Representation Information: Investors can apply to become lead plaintiffs through Robbins Geller Rudman & Dowd LLP, a firm with extensive experience in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strength in such cases.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, covering all securities purchasers between July 23, 2025, and February 3, 2026, highlighting investor concerns over the company's financial transparency.
- False Statements Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, particularly regarding the sustainability of growth in its U.S. electrophysiology segment, severely undermining investor confidence in the company's future.
- Market Reaction: As the company faces adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory hurdles, investor losses may escalate, reflecting a pessimistic outlook on Boston Scientific's future performance in the market.
- Investor Action: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs to participate in potential recoveries, indicating that legal actions could further negatively impact the company's stock price.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, resulting in investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
- Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than firms that merely act as intermediaries, ensuring they receive effective legal support in the class action.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Robbins LLP reminds all investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, that a class action has been filed to protect shareholder rights and seek compensation.
- False Information Allegations: The lawsuit alleges that Boston Scientific misled investors during this period by claiming reliable information regarding the company's revenue outlook, while in reality, it faced new competitors that diminished its market share in U.S. electrophysiology.
- Significant Stock Price Drop: On February 4, 2026, Boston Scientific announced disappointing fourth quarter and full year 2025 results, causing its stock price to plummet from $91.62 to $75.50, a decline of over 17%, reflecting market concerns about the company's growth potential.
- Shareholder Action Guidance: Shareholders can submit their applications by May 4, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, and those who choose not to participate can remain absent class members while still being eligible for recovery.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
Investigation into Boston Scientific Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq LLP is investigating potential securities fraud claims against Boston Scientific, specifically urging investors who purchased securities between July 23, 2025, and February 3, 2026, to contact them before the May 4, 2026, deadline to seek lead plaintiff status.
- Performance Miss Impact: Boston Scientific's February 4, 2026, earnings report revealed disappointing U.S. EP sales, resulting in a significant net income miss and a 17.6% drop in stock price to $75.50 per share, causing substantial losses for investors.
- Management Misrepresentation: The complaint alleges that Boston Scientific and its executives failed to disclose the true state of the U.S. EP segment's growth, leading to a severe loss of investor confidence and negatively impacting market expectations for future performance.
- Legal Rights Reminder: Faruq & Faruq LLP encourages anyone with information regarding Boston Scientific's conduct, including whistleblowers and former employees, to come forward to assist in the litigation process.
See More
Boston Scientific Class Action Lawsuit Notice
- Class Action Timeline: Purchasers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, have until May 4, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential legal risks.
- Allegations Overview: The lawsuit alleges that Boston Scientific and its executives made false or misleading statements during the class period, failing to disclose risks from increased market competition and unmet revenue expectations, which could undermine investor confidence.
- Financial Performance Disclosure: On February 4, 2026, Boston Scientific reported fourth-quarter and full-year 2025 results, revealing a net income increase to $672 million, yet the earnings per share (EPS) fell short of guidance, leading to a stock price drop of over 17%, reflecting market apprehension about the company's outlook.
- Legal Representation Information: Investors can apply to become lead plaintiffs through Robbins Geller Rudman & Dowd LLP, a firm with extensive experience in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strength in such cases.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, covering all securities purchasers between July 23, 2025, and February 3, 2026, highlighting investor concerns over the company's financial transparency.
- False Statements Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, particularly regarding the sustainability of growth in its U.S. electrophysiology segment, severely undermining investor confidence in the company's future.
- Market Reaction: As the company faces adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory hurdles, investor losses may escalate, reflecting a pessimistic outlook on Boston Scientific's future performance in the market.
- Investor Action: Investors must apply by May 4, 2026, to be appointed as lead plaintiffs to participate in potential recoveries, indicating that legal actions could further negatively impact the company's stock price.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, resulting in investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, recovering over $438 million for investors in 2019 alone, highlighting its leadership in the field.
- Investor Guidance: Investors are advised to carefully select experienced legal counsel rather than firms that merely act as intermediaries, ensuring they receive effective legal support in the class action.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Robbins LLP reminds all investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, that a class action has been filed to protect shareholder rights and seek compensation.
- False Information Allegations: The lawsuit alleges that Boston Scientific misled investors during this period by claiming reliable information regarding the company's revenue outlook, while in reality, it faced new competitors that diminished its market share in U.S. electrophysiology.
- Significant Stock Price Drop: On February 4, 2026, Boston Scientific announced disappointing fourth quarter and full year 2025 results, causing its stock price to plummet from $91.62 to $75.50, a decline of over 17%, reflecting market concerns about the company's growth potential.
- Shareholder Action Guidance: Shareholders can submit their applications by May 4, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, and those who choose not to participate can remain absent class members while still being eligible for recovery.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
